Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C

Cancer Chemotherapy and Pharmacology
D TummarelloR Cellerino

Abstract

In a series of 46 symptomatic patients with metastatic, stage IV, non-small-cell lung cancer (NSCLC), we used a three-drug combination with cisplatin (120 mg/m2), vinblastine (6 mg/m2) and mitomycin-C (6 mg/m2) (PVM), repeated every 3 weeks. After two courses, we observed that none of the patients had achieved a complete response; 33% (15/46) had partial response (95% confidence limits: 19.2-46.8); 39% (18/46), stable disease and 28% (13/46), progressive disease. Median response duration was 14.0 weeks (range, 4-36.7), median time to progression 22.4 weeks (range, 7-44.4), and median survival time 26.4 weeks (range, 1-103). WHO grade III-IV myelotoxicity occurred in 15.2% of the courses administered, affecting 39.5% of patients, and severe nephrotoxicity was observed in 9.3% of patients. No toxic death occurred. The post-treatment KPS score increased in 7 patients with partial response (47%), 4 with stable disease (22%) and 1 with progressive disease (8%), while it decreased in 3 patients with partial response (20%), 3 with stable disease (17%) and 10 with progressive disease (77%). In all, KPS increased in 12/46 cases (26%). However, no statistically significant difference was observed when the KPS score before and after treat...Continue Reading

References

Dec 1, 1992·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A MartoniF Pannuti
Aug 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R CellerinoG Fatati
Nov 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P D BonomiR Comis
Jan 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C RuckdeschelS Vogl
Jan 1, 1981·Cancer·A B MillerA Winkler
May 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R GandaraS M Grunberg
Oct 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R GrilliJ A Julian

❮ Previous
Next ❯

Citations

Jun 8, 2001·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·G NumicoM Merlano
May 14, 2009·Current Opinion in Pulmonary Medicine·Orit C Freedman, Camilla Zimmermann
Aug 5, 1998·Quality in Health Care : QHC·A Melville, A Eastwood
Mar 10, 2001·Archives of Physical Medicine and Rehabilitation·A L Cheville
Mar 10, 2001·Cancer Treatment Reviews·W T Bradner
Apr 17, 1998·The American Journal of Hospice & Palliative Care·N M Ellison
Feb 22, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A SocinskiR B Natale
Jul 1, 1997·Cancer Control : Journal of the Moffitt Cancer Center·A ChiapporiD H Johnson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.